Glaukos (GKOS) Earnings, Outlook ‘Brighter’; Shares Soar to All-Time High

Glaukos Corp. (NYSE:GKOS)—an ophthalmic medical technology and pharmaceutical company—soared to a new all-time high on Thursday amid positive catalysts, including strong earnings, a higher growth outlook, and bullish analyst comments.

In intra-day trading, the stock surged to its highest price of $243.71 before paring gains to finish the session just up by 33.65 percent at $242.48 apiece, making it the highest-gaining stock during the market session.

Photo by Tima Miroshnichenko on Pexels

Q3 sales jump bolsters FY26, 2027 growth outlook

The rally was driven by solid third-quarter earnings, with net income rising to $2.018 million from a net loss of $16.2 million in the same period last year.

The higher figures were supported by record net sales of $211 million, or a 58 percent jump from the $133.5 million in the same quarter last year, thanks to strong revenues from iDose TR and Epioxa.

US sales climbed by 47 percent while that from corneal health surged by 154 percent.

READ NEXT: 10 Fastest-Growing AI Stocks to Buy Now

“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” Glaukos Corp. Chairman and CEO Thomas Burns said.

The company also raised its full-year revenue growth outlook to reflect third-quarter results. Revenues are now targeted to end anywhere between $775 million and $785 million, versus the $680 million to $700 million range expected prior.

“We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases,” Burns noted.

For next year, the company is expecting revenues to crack past the $1 billion level based on the latest foreign currency exchange rates.

3 analysts issue ‘buy’ reco

Three investment companies reiterated their buy recommendations in shares of Glaukos Corp., while also raising their price targets for the stock.

DON’T MISS: 10 Stocks You Are Selling and Insiders Are Buying

Needham was the most bullish among all three, raising its price target to $251 from $201 previously, citing the listed firm’s revenue beat driven by Epioxa and its belief in further upside in profitability and revenues for 2027 and beyond.

Meanwhile, BTIG raised its price target to $234 price target from $205, while  Stifel hiked its target to $225 from $190.

Mizuho raised its fair value assessment to $225 from $185, alongside an outperform rating.

Strong Hedge Fund Positioning

Institutional sentiment turned bullish for Glaukos Corp. in the second quarter of the year, as evidenced by the significant jump in committed capital and the number of hedge funds establishing positions in the stock.

Data from Insider Monkey showed that 35 hedge funds held positions in its shares during the period, up from 30 in the quarter previously.

Their combined holdings soared by 52 percent to $1.15 billion from $761 million quarter-on-quarter.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Follow Insider Monkey on Google News.